ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Chongqing Genrix Biopharmaceutical Co., Ltd clinical trials

Part of Chongqing Zhirui Investment Co., Ltd., which holds 54.54% as of 2025-12-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 29 studies whose lead sponsor is Chongqing Genrix Biopharmaceutical Co., Ltd or the company grouped under it. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Chongqing Genrix Biopharmaceutical with Johnson & Johnson and Jiangsu HengRui Medicine →

Pipeline: 5 programs

Each counted once: 5 with a study Chongqing Genrix Biopharmaceutical Co., Ltd leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3

The 2 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Chongqing Genrix Biopharmaceutical Co., Ltd’s own registered studies; Chongqing Genrix Biopharmaceutical Co., Ltd’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Chongqing Genrix Biopharmaceutical Co., Ltd’s studies test, most open studies first — 5 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

5 of Chongqing Genrix Biopharmaceutical Co., Ltd’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. M
  6. A
  7. 2M
  8. 1J
  9. 2J
  10. A
  11. S
  12. O
  13. N

Add all 5 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 19, 2026.

All 29 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1862%Not yet recruiting 10 · Recruiting 8
  • Under way, not recruiting414%
  • Completed724%

Phase

  • Phase 214
  • Phase 112
  • Phase 38

Where

Over the years

  1. 20
  2. 21
  3. 22
  4. 23
  5. 24
  6. 725
  7. 526

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chongqing Genrix Biopharmaceutical Co., Ltd.

  • Genrix (Shanghai) Biopharmaceutical Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    28 studies →
  • Chongqing Genrix Biopharmaceutical Co., Ltd
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study

Studies

Recruiting first, then most recently updated. Showing 29 of 29.